All manufacturers of anti-diabetic drugs have issued press releases on their Q2 earnings. Novo Nordisk on August 9th and Eli Lilly on July 30th. And the 79th Scientific Sessions of the American Diabetes Association took place June 7-11, so a look at the changes in the diabetes landscape is due. Worldwide sale of insulin continues …
Continue reading “Recent developments in the diabetes landscape halfway into 2019”
Teva Pharmaceuticals issued a press release on their Q2 earnings on August 7th. Below are excerpts from the earnings call with CEO Kåre Schultz and outgoing CFO Michael McClellan and relevant figures and slides. Further below the CGRP migraine drugs Ajovy® from Teva, Aimovig® from Amgen and Emgality® from Lilly are discussed. The legacy litigations …
Teva reported on their first quarter results and issued the following press release with the following headlines and statements from the CEO: – Revenues of $4.3 billion – GAAP diluted loss per share of $0.10 – Non-GAAP diluted EPS of $0.60 – Free cash flow of $360 million – Spend base reduction of $2.5 billion …
Novo Nordisk has released their annual report. Positive growth was driven primarily by Ozempic® in the US, Saxenda®, Tresiba® and Victoza®, whereas negative growth was driven by primarily Levemir® in the US. The mentioned drugs and the trailing twelve month (TTM) sales of diabetes and obesity drugs are summarised below. Name Drug Type Injection Therapy …
Diabetes rivals Eli Lilly and Novo Nordisk and their smaller diabetes competitors such as Sanofi, Merck, AstraZeneca and Johnson & Johnson have all released their Q3 results. Below is a summary of Novo and Lilly and their shared therapeutic area diabetes and their shared drug class GLP1. GLP1 receptor agonists come with the HbA1c advantages …
J&J released their Q3 results today: – 2018 Third-Quarter Sales of $20.3 Billion Increased 3.6% versus 2017 – 2018 Third-Quarter EPS was $1.44 – 2018 Adjusted Third-Quarter EPS of $2.05 increased 7.9%* – Strong Operational Sales and Adjusted EPS Growth* – Company Increased Sales and EPS Guidance The Q3 results spawned the following headlines. – …
Continue reading “Johnson & Johnson Reports 2018 Third-Quarter Results”
Today Ely Lilly (LLY) announced the positive results on a phase 2 diabetes drug of theirs (LY3298176) via a publication in The Lancet, a presentation at the annual meeting of the European Association for the Study of Diabetes (EASD) and the press release below: Lilly’s Investigational Dual GIP and GLP-1 Receptor Agonist Shows Significant Reduction …
Continue reading “Eli Lilly and phase results 2 on their dual GIP/GLP1 receptor agonist LY3298176”
Teva announced the FDA approval of their migraine drug Ajovy® (Fremanezumab) – a mAB CGRP inhibitor – in a press release on September 21st. I felt it would be a good time to revisit Teva and migraine drugs, since a lot of things have happened, since their largest ever acquisition of Actavis Generics from Allergan …
Continue reading “Teva and the approval of the migraine drug Ajovy®”